Acer Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ACER, and when can generic versions of ACER drugs launch?
ACER has three approved drugs.
There are eleven US patents protecting ACER drugs.
There are one hundred and forty-seven patent family members on ACER drugs in thirty-five countries and seventy-three supplementary protection certificates in ten countries.
Summary for Acer
| International Patents: | 147 |
| US Patents: | 11 |
| Tradenames: | 3 |
| Ingredients: | 3 |
| NDAs: | 3 |
Drugs and US Patents for Acer
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Acer | OLPRUVA | sodium phenylbutyrate | FOR SUSPENSION;ORAL | 214860-001 | Dec 22, 2022 | RX | Yes | No | 11,433,041 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Acer | OLPRUVA | sodium phenylbutyrate | FOR SUSPENSION;ORAL | 214860-004 | Dec 22, 2022 | RX | Yes | No | 11,154,521 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Acer | OLPRUVA | sodium phenylbutyrate | FOR SUSPENSION;ORAL | 214860-006 | Dec 22, 2022 | RX | Yes | Yes | 11,154,521 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Acer
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Acerus | NATESTO | testosterone | GEL, METERED;NASAL | 205488-001 | May 28, 2014 | 8,574,622 | ⤷ Sign Up |
| Acerus Pharms | NOCTIVA | desmopressin acetate | SPRAY, METERED;NASAL | 201656-001 | Mar 3, 2017 | 7,579,321 | ⤷ Sign Up |
| Acerus | NATESTO | testosterone | GEL, METERED;NASAL | 205488-001 | May 28, 2014 | 8,784,882 | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Acer Drugs
Supplementary Protection Certificates for Acer Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1856135 | CA 2020 00018 | Denmark | ⤷ Sign Up | PRODUCT NAME: FOSTAMATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, OR A HYDRATE, SOLVATE OR N-OXIDE OF FOSTAMATINIB OR THE PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, ESPECIALLY FOSTAMATINIB DISODIUM, OPTIONALLY IN FORM OF A HYDRATE; REG. NO/DATE: EU/1/19/1405 20200113 |
| 0788511 | SPC/GB08/036 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: MICAFUNGIN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF IN PARTICULAR MICAFUNGIN SODIUM; REGISTERED: UK EU/1/08/448/001 20080425; UK EU/1/08/448/002 20080425 |
| 2712622 | LUC00015 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: DESMOPRESSINE OU UN DE SES SELS D'ACETATE; AUTHORISATION NUMBER AND DATE: 497271; 497280 20161101 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
